Global Lung Cancer Therapeutics Industry Insights Report 2015-2019

Global Lung Cancer Therapeutics Market 2015-2019 is the latest addition to industry research reports collection.

Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diagnosed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Small cell lung cancers form roughly 10-15 percent of all the diagnosed cases of lung cancer. There are two types of small cell lung cancer: small cell carcinoma and combined small cell carcinoma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer cannot be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, and wheezing. Both small cell lung cancer and non-small cell lung cancer are recurrent in nature, which are difficult to cure.

Analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 3.83 percent over the period 2014-2019.

Single User License of the report is Available at US $3000

This report covers the present scenario and the growth prospects of the Global Lung Cancer Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of non-small cell lung cancer and small cell lung cancer.

The Global Lung Cancer Therapeutics market is segmented based on the type of molecule used for the treatment of lung cancer, which include:

·      • Biologics

·         • Small molecules

In addition, the market is also segmented based on the route of administration followed for the treatment of lung cancer, which include:

·         • Oral

·         • Parenteral

Global Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Order a copy of this report at (Prices start at US $3000 for a single user PDF) .

Key Regions

·         • Americas

·         • APAC

·         • EMEA

Key Vendors

·         • AstraZeneca

·         • Celgene

·         • Eli Lilly

·         • F. Hoffmann-La Roche

·         • Pfizer

Other Prominent Vendors

·         • Abbvie

·         • Aetna

·         • Agennix

·         • Amgen

·         • Boehringer Ingelheim

·         • Celldex

·         • Eisai

·         • GlaxoSmithKline

·         • GTx

·         • Helsinn

·         • IMClone

·         • Merck Serono

·         • Novartis

·         • Qiagen

·         • OncoGenex

·         • OSI Pharmaceuticals

·         • Peregrine

·         • Pierre Fabre

·         • Sanofi

·         • Synta

·         • Telik

·         • Teva Pharmaceutical


Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disease Overview
08. Market Landscape
09. Market Segmentation by Disease Type
10. Market Segmentation by Molecule Type
11. Market Segmentation by Route of Administration
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape21. Pipeline Portfolio
22. Key Vendor Analysis
23. Other Reports in this Series

List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Incidence Data of Lung Cancer pertaining to WHO Regions
Exhibit 3: Classification of Lung Cancer Types
Exhibit 4: Diagnosis of Lung Cancer in Patients
Exhibit 5: Staging of Small Cell Lung Cancer
Exhibit 6: Stepwise Diagrammatic Representation of the Management of Small Cell Lung Cancer According to the ESMO Guidelines
Exhibit 7: Types of Non-small Cell Lung Cancer
Exhibit 8: Percentage of Gene Mutations in Non-small Cell Lung Cancer
Exhibit 9: Staging of Non-small Cell Lung Cancer
Exhibit 10: Global Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Read all 72 Exhibits

Have any Query on the Report get your Queries Resolved at .

About US: ( is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.